Hydrogel as well as preparation method and application thereof

By using tricarboxylic acid cycle intermediate metabolites and methacrylated gelatin in hydrogels, a stable energy active coated structure is formed, which solves the problem of poor stability of exogenous ATP in the body and improves the repair of articular cartilage damage Effect.

CN118986854AActive Publication Date: 2024-11-22HUAZHONG UNIV OF SCI & TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411111133.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-22
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

In the prior art, the externally added ATP has poor stability in vivo, resulting in poor long-term repair effect of articular cartilage damage.

Method used

A hydrogel containing intermediate metabolites of the tricarboxylic acid cycle as energy active substances, and using methacrylate gelatin as gel material, the hydrogel is formed by photoinitiator and ultraviolet light irradiation to coat energy active substances to improve its stability in the body.

Benefits of technology

By accelerating the energy metabolism level of joint cartilage tissues, promoting the repair of joint cartilage, and through the use of highly biocompatible materials, avoiding the instability of ATP, and improving the repair effect of joint cartilage damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986854A_ABST
    Figure CN118986854A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of gel materials, in particular to hydrogel as well as a preparation method and application thereof. The hydrogel comprises an energy active matter and a gel material coating the energy active matter, and the energy active matter is an intermediate metabolite of tricarboxylic acid cycle; the molar concentration of the intermediate metabolite is not less than 0.1 mol / L; an intermediate metabolite of tricarboxylic acid circulation is added into the hydrogel material to serve as an energy active matter, so that the energy metabolism level of the injured tissue part of the articular cartilage can be accelerated, and tissue repair of the articular cartilage is promoted; meanwhile, due to the fact that the biocompatibility of the hydrogel material is high, intermediate metabolites can be stably degraded in the body by coating the energy active matter with the hydrogel, and therefore the defect that the stability of ATP externally added in the body is poor in the body can be overcome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of gel materials, and in particular to a hydrogel and a preparation method and application thereof. Background Art

[0002] Articular cartilage injury is an injury-related disease caused by joint diseases, sports trauma or aging. On the one hand, the lack of vascular network in articular cartilage makes the nutrient delivery efficiency low. On the other hand, the lack of proliferating cells in articular cartilage makes the articular cartilage lack the ability to repair itself. The above factors make the treatment of articular cartilage injury more difficult. At present, the main clinical treatments for articular cartilage injury include microfracture, autologous transplantation, and allogeneic transplantation. However, these treatments are prone to form fibrotic cartilage or hypertrophic cartilage, resulting in low quality of articular cartilage repair. In addition, the presence of matrix-degrading enzymes at the site of cartilage injury can easily degrade the new cartilage, resulting in poor long-term repair of articular cartilage injury.

[0003] Existing studies have shown that the anabolism of articular chondrocytes and the highly ordered arrangement of their extracellular matrix (ECM) are one of the most energy-consuming processes in the human extracellular space. Adding a certain amount of exogenous ATP can promote the production of cartilage cell extracellular matrix through the interaction of a series of signal pathways, thereby enhancing the mechanical strength of tissue-engineered cartilage; in addition, a certain concentration of exogenous ATP can also inhibit the expression of matrix-degrading enzyme MMP-13 in chondrocytes, thereby inhibiting the degradation of extracellular matrix to maintain the cartilage phenotype. However, the stability of exogenously added ATP in the body is poor, so it cannot provide kinetic energy for the defect site of articular cartilage for a long time. Summary of the invention

[0004] The present application provides a hydrogel and a preparation method and application thereof, so as to solve the technical problem in the prior art that exogenously added ATP has poor stability in vivo.

[0005] In a first aspect, the present application provides a hydrogel, comprising an energy active substance and a gel material encapsulating the energy active substance, wherein the energy active substance is an intermediate metabolite of a tricarboxylic acid cycle; and the molar concentration of the intermediate metabolite is ≥0.1 mol / L.

[0006] Optionally, the intermediate metabolite includes at least one of the following:

[0007] Alpha-ketoglutarate, citric acid, succinic acid and malic acid.

[0008] Optionally, the intermediate metabolite includes succinic acid.

[0009] Optionally, the gel material includes methacrylated gelatin, and the mass ratio of the methacrylated gelatin to the gel material is 5% to 10%.

[0010] In a second aspect, the present application provides a method for preparing the hydrogel according to the first aspect, the method comprising:

[0011] Mixing the energy active substance and the coupling agent to obtain a mixed solution;

[0012] Stirring and mixing the mixed solution and the gel material to obtain a mixed gel solution;

[0013] dialyzing the mixed gel solution, and then freeze-drying the dialyzed mixed gel solution to obtain a freeze-dried product;

[0014] Diluting the freeze-dried product to a preset mass concentration using a photoinitiator to obtain a gel solution;

[0015] irradiating the gel solution with ultraviolet light to obtain a hydrogel product;

[0016] Wherein, the energy active substance is an intermediate metabolite of the tricarboxylic acid cycle.

[0017] Optionally, the preset mass concentration is ≥10%.

[0018] Optionally, the molar ratio of the energy active substance to the coupling agent is 1:1-2.

[0019] Optionally, the coupling agent includes 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and / or N-hydroxysuccinimide.

[0020] Optionally, the molecular weight cutoff used for the dialysis is 8000D to 14000D.

[0021] In a third aspect, the present application provides an application of a hydrogel, wherein the application comprises using the hydrogel described in the first aspect in a drug for repairing articular cartilage damage.

[0022] The above technical solution provided by the embodiment of the present application has the following advantages compared with the prior art:

[0023] A hydrogel provided in an embodiment of the present application, by adding intermediate metabolites of the tricarboxylic acid cycle into the hydrogel material to act as energy active substances, since the intermediate metabolites of the tricarboxylic acid cycle can oxidize FADH2 and produce FAD through the tricarboxylic acid cycle, the intermediate metabolites can participate in the process of electron transfer and promote ATP synthesis, and the synthesized ATP can provide biological energy for tissue cells, and the intermediate metabolites can also improve the level of mitochondrial fusion and fission in tissue cells, thereby accelerating the energy metabolism level of the damaged tissue of articular cartilage to promote tissue repair of articular cartilage; at the same time, due to the high biocompatibility of the hydrogel material, the intermediate metabolites can be stably degraded in the body by coating the energy active substance with the hydrogel, thereby avoiding the defect of poor stability of exogenously added ATP in the body. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0025] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0026] Figure 1 This is a scanning electron microscope characterization image of a hydrogel provided in Example 1 of the present application;

[0027] Figure 2 This is the hydrogen nuclear magnetic resonance spectrum of the freeze-dried product provided in Example 1 of the present application;

[0028] Figure 3 A comparison chart of cell activity in the hydrogels of the hydrogel products provided in Example 1 and Comparative Example 1 of the present application on the seventh day of the cell compatibility experiment;

[0029] Figure 4 A comparison chart of the results of the hydrogel products provided in Example 1 of the present application and Comparative Example 1 in an experiment on promoting cell proliferation;

[0030] Figure 5 A comparison chart of the results of the hydrogel products provided in Example 1 and Comparative Example 1 of the present application in the cellular ATP level effect experiment;

[0031] Figure 6 This is a graph showing the surface cell mitochondrial membrane potential results of the hydrogel products provided in Example 1 and Comparative Example 1 of the present application in a cell mitochondrial membrane potential energy experiment, wherein: Figure 6A is the fluorescence image of the surface cell mitochondrial membrane potential of the hydrogel product in the cell mitochondrial membrane potential energy experiment. Figure 6 B is the statistical diagram of the fluorescence quantity of the surface cell mitochondrial membrane potential of the hydrogel product in the cell mitochondrial membrane potential energy experiment;

[0032] Figure 7 This is a fluorescence result diagram of the hydrogel product provided in Example 1 and Comparative Example 1 of the present application in an experiment of promoting BMSCs to differentiate into chondrocytes;

[0033] Figure 8 A schematic flow chart of a method for preparing a hydrogel product provided in an embodiment of the present application. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0035] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in this application can be purchased from the market or prepared by existing methods.

[0036] It should be noted that hydrogels are widely used in the research field of cartilage repair due to their diversity of choices, high water content and convenient adjustment of mechanical properties. However, hydrogels in cartilage repair are currently used as encapsulation materials for seed cells and growth factors, or as support materials for scaffolds, for example:

[0037] (1) Repair is performed using hydrogel loaded with bone marrow mesenchymal stem cells (BMSC) containing TGF-β-miRNA-extracellular vesicles, but the seed cell culture steps are complicated and the repair efficiency is low.

[0038] (2) A hydrogel scaffold was synthesized using methacrylated chondroitin sulfate and polylactide-caprolactone-polyethylene glycol-polylactide-caprolactone (PLCL-PEG-PLCL) triblock copolymer and used for cartilage damage. However, this technology did not promote the repair of articular cartilage from the perspective of regulating cellular energy metabolism.

[0039] Therefore, how to improve the stability of added ATP through hydrogel materials is a technical problem that needs to be solved urgently.

[0040] like Figure 1As shown, an embodiment of the present application provides a hydrogel, which includes an energy active substance and a gel material coating the energy active substance, wherein the energy active substance is an intermediate metabolite of the tricarboxylic acid cycle; the molar concentration of the intermediate metabolite is ≥0.1 mol / L; in these embodiments, the molar concentration of the intermediate metabolite can be ≥0.1 mol / L, because the intermediate metabolite can improve the effect of the tricarboxylic acid cycle process in the articular cartilage tissue cells, so as to accelerate the energy metabolism level of the damaged tissue of the articular cartilage and promote the tissue repair of the articular cartilage.

[0041] In some optional embodiments, the intermediate metabolite includes at least one of the following:

[0042] α-ketoglutarate, citric acid, succinic acid, and malic acid;

[0043] In some optional embodiments, the intermediate metabolites include succinic acid; in these embodiments, the intermediate metabolites such as α-ketoglutaric acid, citric acid, succinic acid and malic acid can cover most of the products of the tricarboxylic acid cycle, and these intermediate metabolites can improve the effect of the tricarboxylic acid cycle process in articular cartilage tissue cells, so as to accelerate the energy metabolism level of the damaged tissue of articular cartilage and promote the tissue repair of articular cartilage.

[0044] It should be noted that the biological enzymes used for α-ketoglutarate, citric acid, malic acid and succinic acid in the tricarboxylic acid cycle are ketoglutarate dehydrogenase, citrate synthase, isocitrate dehydrogenase and succinate dehydrogenase respectively, and ketoglutarate dehydrogenase, citrate synthase, isocitrate dehydrogenase and succinate dehydrogenase are all key enzymes of the tricarboxylic acid cycle, but the catalytic efficiency of ketoglutarate dehydrogenase, citrate synthase and isocitrate dehydrogenase is lower than that of succinate dehydrogenase. In addition, ketoglutarate dehydrogenase, citrate synthase and isocitrate dehydrogenase are the determining steps of the tricarboxylic acid cycle, and exogenous succinic acid can bypass the rate-limiting process of the tricarboxylic acid cycle to accelerate the energy metabolism level of the defective tissue of articular cartilage. At the same time, exogenous succinic acid can promote the tissue repair of articular cartilage.

[0045] In some optional embodiments, the gel material includes methacrylated gelatin, and the mass ratio of the methacrylated gelatin to the gel material is 5% to 10%; it should be noted that methacrylated gelatin (GelMA) has the characteristics of both natural and synthetic materials, and GelMA has a three-dimensional structure suitable for cell growth and cell differentiation and excellent biocompatibility, so GelMA can replace artificial basement membrane or natural collagen and increase the growth rate of cells; in these embodiments, the mass ratio of methacrylated gelatin to the gel material can be 5% to 10%, and methacrylated gelatin can be used to improve the biocompatibility of the gel material and at the same time improve the stability of intermediate metabolites in the gel material.

[0046] like Figure 8 As shown, based on a general inventive concept, an embodiment of the present application provides a method for preparing the hydrogel, the method comprising:

[0047] S1. mixing the energy active substance and the coupling agent to obtain a mixed solution;

[0048] S2. stirring and mixing the mixed solution and the gel material to obtain a mixed gel solution;

[0049] S3. dialyzing the mixed gel solution, and then freeze-drying the dialyzed mixed gel solution to obtain a freeze-dried product;

[0050] S4. diluting the freeze-dried product to a preset mass concentration using a photoinitiator to obtain a gel solution;

[0051] S5. irradiating the gel solution with ultraviolet light to obtain a hydrogel product;

[0052] Among them, the energy active substance is an intermediate metabolite of the tricarboxylic acid cycle; in these embodiments, a gel material is first prepared, and the energy active substance and the coupling agent are mixed at the same time, so that the energy active substance in the subsequent mixed solution can be coupled with the gel material, so that the energy active substance can be encapsulated in the gel material to obtain a mixed gel solution, and then the mixed gel solution is purified by dialysis, and then the purified mixed gel solution is further purified by freeze-drying to obtain a freeze-dried product, and finally the freeze-dried product is diluted by a photoinitiator, so that the mass concentration of the energy active substance in the freeze-dried product is 0.4 mol / L to obtain a gel solution, and finally the gel solution is irradiated with ultraviolet light to form a hydrogel product by light initiation.

[0053] This method is a method for preparing the above-mentioned hydrogel. The specific composition of the gel can refer to the above-mentioned embodiment. Since this method adopts part or all of the technical solutions of the above-mentioned embodiment, it at least has all the beneficial effects brought by the technical solutions of the above-mentioned embodiment, which will not be described one by one here.

[0054] It should be noted that the gel material may be a gelatin solution, and the mass concentration of the gelatin solution may be 6%.

[0055] It should be noted that the photoinitiator can be a lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) solution, and the mass concentration of the initiator is 0.5%.

[0056] In some optional embodiments, the preset mass concentration is ≥10%; in these embodiments, the preset mass concentration may be ≥10%, which may indicate that the amount of photoinitiator added is sufficient at this time, so that the photoinitiator may induce a chemical reaction of the freeze-dried product under ultraviolet light conditions during the subsequent hydrogel preparation stage, thereby causing the gel solution to form a hydrogel product.

[0057] In some optional embodiments, the molar ratio of the energy active substance to the coupling agent is 1:1-2; in these embodiments, the molar ratio of the energy active substance to the coupling agent can be 1:1-2. During the stirring and mixing process in the subsequent hydrogel preparation stage, the energy active substance can be cross-linked with the gel material through the coupling agent, thereby promoting the energy active substance to enter the gel material to obtain a hydrogel product.

[0058] The molar ratio of the energy active substance to the coupling agent can be 1:10, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9 or 1:20.

[0059] In some optional embodiments, the coupling agent includes 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and / or N-hydroxysuccinimide; in these embodiments, the coupling agent may include 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and / or N-hydroxysuccinimide (NHS), and the energy active substance may be promoted through the biological coupling reaction between EDC and / or NHS in the coupling agent.

[0060] In some optional embodiments, the molecular weight cutoff used for dialysis is 8000D-14000D; in these embodiments, the molecular weight cutoff used for dialysis can be 8000D-14000D, which can fully remove impurities in the mixed gel solution to obtain a pure mixed gel solution.

[0061] The molecular weight cutoff used for the dialysis can be 8000D, 8500D, 9000D, 9500D, 10000D, 10500D, 11000D, 11500D, 12000D, 12500D, 13000D, 13500D or 14000D.

[0062] Based on a general inventive concept, an embodiment of the present application provides an application of a hydrogel, wherein the application includes using the hydrogel in a repair drug for articular cartilage damage.

[0063] This application is realized based on the above-mentioned hydrogel. The specific composition of the hydrogel can refer to the above-mentioned embodiment. Since this application adopts part or all of the technical solutions of the above-mentioned embodiment, it has at least all the beneficial effects brought by the technical solutions of the above-mentioned embodiment, which will not be described one by one here.

[0064] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are intended only to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are usually measured according to industry standards. If there is no corresponding industry standard, then the conditions recommended by the manufacturer are followed.

[0065] Example 1

[0066] 1. A method for preparing a hydrogel with bioenergy activity, the specific steps are as follows:

[0067] (1) Succinic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide were weighed in a molar ratio of 1:1:1, mixed, and then dissolved in 100 mL of ultrapure water to obtain an aqueous solution. The pH of the aqueous solution was adjusted to 4.7, and then the aqueous solution was subjected to a chemical reaction for 3 h at room temperature in the dark to obtain a mixed solution.

[0068] (2) The mixed solution is slowly added dropwise to the gel material (using gelatin solution), the pH value of the addition process is maintained at 4.7, and magnetic stirring is used for mixing. Then, the gel material and the mixed solution are reacted at a temperature of 25° C. for 12 hours to obtain a mixed gel solution.

[0069] (3) The mixed gel solution was dialyzed using a dialysis bag of 8000D to 14000D and ultrapure water. The dialyzed solution was replaced three times a day during the dialysis process. The dialysis was performed for a total of three days to obtain a dialyzed mixed gel solution.

[0070] (4) The mixed gel solution after dialysis is freeze-dried to obtain a freeze-dried product GelMA-SA having bioenergetic activity. The synthesized freeze-dried product is characterized by nuclear magnetic resonance hydrogen spectrum. The results are as follows: Figure 2 shown.

[0071] (5) Weigh the freeze-dried product and dilute it with 0.5% lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) to a GelMA-SA gel solution with a mass concentration of 10% methacrylated gelatin.

[0072] (6) The gel solution was irradiated with ultraviolet light for 1 min to obtain a GelMA-SA hydrogel product.

[0073] The hydrogel product was freeze-dried to obtain a gel freeze-dried product, and the gel freeze-dried product was observed by scanning electron microscopy. The characterization results are as follows: Figure 1 shown.

[0074] Example 2

[0075] Comparing Example 2 with Example 1, the difference between Example 2 and Example 1 is:

[0076] The molar ratio of succinic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide is 1:0.5:0.5.

[0077] Example 3

[0078] Comparing Example 3 with Example 1, the difference between Example 3 and Example 1 is:

[0079] The molar ratio of succinic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide is 1:0.75:0.75.

[0080] Comparative Example 1

[0081] 2. A method for preparing a hydrogel by ultraviolet crosslinking, the specific steps are as follows:

[0082] (1) First, prepare a gelatin solution with a mass concentration of 6% by dissolving gelatin in a water bath at a temperature of 36°C to obtain a gelatin solution.

[0083] (2) Glycidyl methacrylate with a mass concentration of 8% was added dropwise to the gelatin solution, and then the mixture was subjected to magnetic stirring reaction at a temperature of 36° C. for 20 h to obtain a mixed solution.

[0084] (3) The mixed solution was centrifuged at 5000 rpm for 5 min, and the supernatant was retained.

[0085] (4) The supernatant was dialyzed using a 8000D to 14000D dialysis bag and ultrapure water, and the dialyzation was performed for three days with the solution being changed three times a day to obtain a gel solution.

[0086] (5) freeze-drying the gel solution to obtain a freeze-dried product, methacrylated gelatin material.

[0087] (6) Weigh the freeze-dried product and dilute it with LAP at a mass concentration of 0.5% to a GelMA gel solution at a mass concentration of 10%.

[0088] (7) The GelMA gel solution was irradiated with ultraviolet light for 1 min to obtain a GelMA hydrogel product.

[0089] Related experiments and results:

[0090] The following experiments were performed on the hydrogel products of Example 1 and Comparative Example 1 respectively:

[0091] 3. Verify the cell compatibility of the bioenergy active hydrogel. The specific steps are as follows:

[0092] (1) The hydrogel products of Example 1 and Comparative Example 1 were respectively prepared into 10% pre-gel solutions using LAP solution, and then subjected to in vitro experiments:

[0093] 1) Bone marrow mesenchymal stem cells (BMSCs) were cultured at a rate of 10×10 5 The cells were mixed with 500 μL of pre-gel solution at a density of 100 μg / mL and then irradiated with ultraviolet light for 1 min to obtain a gel-BMSCs complex.

[0094] 2) The complex was cultured in a 48-well plate for 7 days and then fluorescently stained using a live-dead staining kit to characterize the complex.

[0095] The results are as follows Figure 3 As shown, compared with Comparative Example 1, the BMSCs cells in the hydrogel product of Example 1 can survive for a long time, and the survival rate of the BMSCs cells is higher.

[0096] 4. Verify the effect of bioenergy active hydrogel products in promoting cell proliferation. The specific steps are as follows:

[0097] (1) First, 100 μL of the pre-gel solutions of Example 1 and Comparative Example 1 were respectively measured and placed in a 96-well plate, and the pre-gel solutions were evenly spread on the bottom of the wells. The plates were then irradiated with ultraviolet light for 1 min to form a hydrogel.

[0098] (2) Rat bone marrow mesenchymal stem cells (BMSCs) of passage 5 to 8 were collected and cultured at a rate of 5 × 10 3 The cells were seeded at a density of 100 cells / mL in a 96-well plate with prepared hydrogels.

[0099] (3) CCK-8 was used to measure the proliferation of cells in 96-well plates on the 1st, 5th and 7th days.

[0100] The results are as follows Figure 4 As shown, this indicates that the bioenergetic active hydrogel in Example 1 can promote the proliferation of bone marrow mesenchymal stem cells.

[0101] 5. Verify the effect of bioenergetic active hydrogel in increasing cellular ATP levels. The specific steps are as follows:

[0102] (1) First, 100 μL of the pre-gel solutions of Example 1 and Comparative Example 1 were respectively measured and placed in a 96-well plate, and the pre-gel solutions were evenly spread on the bottom of the wells. The plates were then irradiated with ultraviolet light for 1 min to allow the pre-gel solutions to form hydrogels.

[0103] (2) Rat bone marrow mesenchymal stem cells (BMSCs) of passage 5 to 8 were collected and cultured at a rate of 5 × 10 3 The cells were seeded at a density of 100 cells / mL in a 96-well plate with the prepared hydrogels.

[0104] (3) On the first, second, and third day, an ATP detection kit was used to measure the ATP content of cells in the 96-well plate.

[0105] The results are as follows Figure 5 As shown, the ATP expression level of the hydrogel product with bioenergetic activity provided in Example 1 is significantly increased compared with that of the hydrogel product in Comparative Example 1, which indicates that the hydrogel with bioenergetic activity can increase the ATP level of bone marrow mesenchymal stem cells.

[0106] 6. Verify the effect of bioenergetic active hydrogel on cell mitochondrial membrane potential energy. The specific steps are as follows:

[0107] (1) First, 200 μL of the pre-gel solution of Example 1 and Comparative Example 1 was taken into a 6-well plate, and the pre-gel solution was evenly spread on the bottom of the well, and then irradiated with ultraviolet light for 1 min to make the pre-gel solution form a hydrogel.

[0108] (2) Bone marrow mesenchymal stem cells (BMSCs) were cultured at a rate of 2×105 The cells were seeded at a density of 10 cells / mL in a 6-well plate with prepared hydrogels.

[0109] (3) After 3 days of culture, the cells were divided into groups according to the negative control group, comparative example 1 group (GelMA), and example 1 group (GelMA-SA). The negative control group was treated with a culture medium containing an oxidative phosphorylation uncoupler (CCCP).

[0110] The results are as follows Figure 6 A and Figure 6 As shown in B, the results show that the hydrogel with bioenergetic activity in Example 1 can increase mitochondrial membrane potential (ΔΨm) compared with Comparative Example 1, and can better provide ATP for cells.

[0111] 7. Verify the potential of bioenergetic active hydrogel to promote BMSCs differentiation into chondrocytes. The specific steps are as follows:

[0112] (1) First, 200 μL of the pre-gel solution of Example 1 and Comparative Example 1 was taken into a 6-well plate, and the pre-gel solution was evenly spread on the bottom of the well, and then irradiated with ultraviolet light for 1 min to make the pre-gel solution form a hydrogel.

[0113] (2) Bone marrow mesenchymal stem cells (BMSCs) were cultured at a rate of 2×10 5 The cells were seeded at a density of 10 cells / mL in a 6-well plate with prepared hydrogels.

[0114] (3) After culturing the 6-well plate for 24 h, chondrogenic differentiation medium was added to the BMSCs cells in the 6-well plate, and then the synthesis of type II collagen was detected using COL2A antibody on the 14th day.

[0115] The results are as follows Figure 7 As shown, compared with the control group 1 (GelMA), the GelMA-SA of the example 1 group significantly enhanced the synthesis capacity of type II collagen after stimulating BMSCs cells to induce differentiation for 14 days, which indicates that the hydrogel product with bioenergetic activity provided by Example 1 can promote the formation of type II collagen, a marker for the differentiation of bone marrow mesenchymal stem cells into cartilage.

[0116] In summary, the hydrogel provided in the embodiments of the present application can accelerate the energy metabolism level of damaged articular cartilage tissue by adding intermediate metabolites of the tricarboxylic acid cycle into the hydrogel material as energy active substances, so as to promote the tissue repair of articular cartilage; at the same time, due to the high biocompatibility of the hydrogel material, the intermediate metabolites can be stably degraded in the body by coating the energy active substances with the hydrogel, thereby avoiding the defect of poor stability of exogenously added ATP in the body; the material source of the overall hydrogel product is simple and economical, and it is easy to convert and produce.

[0117] In addition, the method for preparing a hydrogel provided in an embodiment of the present application uses a photoinitiator to carry out the gelation process in the hydrogel preparation stage, so the hydrogel also has good photosensitivity, and the hydrogel can quickly form a hydrogel product within 10 seconds. The rapid molding process can avoid damage caused by long-term light stimulation.

[0118] At the same time, the embodiment of the present application provides a method for preparing a hydrogel. The preparation method has a simple process and can prepare a hydrogel with excellent cell compatibility, while also promoting the differentiation of bone marrow mesenchymal stem cells into articular chondrocytes.

[0119] At the same time, a method for preparing a hydrogel provided in an embodiment of the present application uses ultraviolet light cross-linking technology to adjust the shape of the hydrogel product, allowing the hydrogel material to fit well to the defective part of the articular cartilage. At the same time, the hydrogel material also has stable mechanical properties, which can accelerate the repair process of the articular cartilage defect.

[0120] In addition, the application of a hydrogel provided in an embodiment of the present application has good cell compatibility and a high ability to promote articular cartilage differentiation because the hydrogel product uses the intermediate metabolites of the tricarboxylic acid cycle as energy active substances and also uses methacrylated gelatin as a gel material; and the hydrogel that is not initiated by a photoinitiator has good fluidity and good injectability, which makes the operation of the hydrogel simple and easy during the application stage. In addition, the good fluidity allows the hydrogel to fit well to the defective part of the articular cartilage.

[0121] Various embodiments of the present application may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present application; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values ​​within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.

[0122] In the present application, in the absence of any contrary description, the directional words used, such as "upper" and "lower", are specifically the directions of the drawings in the accompanying drawings. In addition, in the description of the present specification, the terms "including", "comprising", etc. refer to "including but not limited to". In this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. In this article, "and / or" describes the association relationship of the associated objects, indicating that there may be three relationships, for example, A and / or B, which can represent: A exists alone, A and B exist at the same time, and B exists alone. Wherein A, B can be singular or plural. In this article, "at least one" refers to one or more, and "plural" refers to two or more. "At least one", "at least one of the following" or similar expressions refer to any combination of these items, including any combination of singular or plural items. For example, "at least one of a, b, or c", or "at least one of a, b and c", can both mean: a, b, c, ab (i.e. a and b), ac, bc or abc, where a, b, c can be single or plural, respectively.

[0123] The above description is only a specific implementation of the present application, so that those skilled in the art can understand or implement the present application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to the embodiments shown herein, but will conform to the widest range consistent with the principles and novel features applied for herein.

Claims

1. A hydrogel, characterized in that: The hydrogel comprises an energy active substance and a gel material covering the energy active substance, wherein the energy active substance is an intermediate metabolite of a tricarboxylic acid cycle; and the molar concentration of the intermediate metabolite is ≥0.1 mol / L.

2. The hydrogel according to claim 1, characterized in that The intermediate metabolites include at least one of the following: Alpha-ketoglutarate, citric acid, succinic acid and malic acid.

3. The hydrogel according to claim 1 or 2, characterized in that The intermediate metabolites include succinic acid.

4. The hydrogel according to claim 1, characterized in that The gel material comprises methacrylated gelatin, and the mass ratio of the methacrylated gelatin to the gel material is 5% to 10%.

5. A method for preparing the hydrogel according to any one of claims 1 to 4, characterized in that: The method comprises: Mixing the energy active substance and the coupling agent to obtain a mixed solution; Stirring and mixing the mixed solution and the gel material to obtain a mixed gel solution; dialyzing the mixed gel solution, and then freeze-drying the dialyzed mixed gel solution to obtain a freeze-dried product; Diluting the freeze-dried product to a preset mass concentration using a photoinitiator to obtain a gel solution; irradiating the gel solution with ultraviolet light to obtain a hydrogel product; Wherein, the energy active substance is an intermediate metabolite of the tricarboxylic acid cycle.

6. The method according to claim 5, characterized in that The preset mass concentration is ≥10%.

7. The method according to claim 5, characterized in that The molar ratio of the energy active substance to the coupling agent is 1:1-2.

8. The method according to claim 5, characterized in that The coupling agent includes 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and / or N-hydroxysuccinimide.

9. The method according to claim 5, characterized in that The molecular weight cutoff used for the dialysis is 8000D to 14000D.

10. An application of a hydrogel, characterized in that: The application includes using the hydrogel as described in any one of claims 1 to 4 in a drug for repairing articular cartilage damage.

Citation Information

Patent Citations

  • GelMA hydrogel as well as preparation method and application thereof

    CN117138110A

  • Preparation method and application of tricarboxylic acid cycle metabolite salt ion modified bone repair hydrogel

    CN117838923A

  • External information recognizing and information providing method using blockchain

    KR1020210056744A

  • Biomaterial for articular cartilage maintenance and treatment of arthritis

    US20140369984A1

  • Modified gelatins, hydrogels, and processes for their production

    WO2024113021A1